DK174965B1 - Praktisk taget rent, antigenisk peptid eller protein med en epitop af Haemophilus influenzae samt underenhedsvaccineformeluring, hvori immungenet indeholder peptidet eller proteinet - Google Patents

Info

Publication number

DK174965B1

DK174965B1 DK199100358A DK35891A DK174965B1 DK 174965 B1 DK174965 B1 DK 174965B1 DK 199100358 A DK199100358 A DK 199100358A DK 35891 A DK35891 A DK 35891A DK 174965 B1 DK174965 B1 DK 174965B1

Authority

DK

Denmark

Prior art keywords

pbomp

protein

dna

peptide

proteins

Prior art date

1988-09-01

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000623 proteins and genes Proteins 0.000 title claims abstract description 405
• 102000004169 proteins and genes Human genes 0.000 title claims abstract description 237
• 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 179
• 241000606768 Haemophilus influenzae Species 0.000 title claims abstract description 139
• 239000000203 mixture Substances 0.000 title claims abstract description 64
• 238000009472 formulation Methods 0.000 title claims abstract description 32
• 230000000890 antigenic effect Effects 0.000 title claims description 20
• 229940031626 subunit vaccine Drugs 0.000 title claims description 16
• 229940124855 Haemophilus influenzae vaccine Drugs 0.000 title 1
• 108020001507 fusion proteins Proteins 0.000 claims abstract description 69
• 102000037865 fusion proteins Human genes 0.000 claims abstract description 68
• 229940047650 haemophilus influenzae Drugs 0.000 claims abstract description 12
• 241000588724 Escherichia coli Species 0.000 claims description 99
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
• 230000002163 immunogen Effects 0.000 claims description 20
• 125000000539 amino acid group Chemical group 0.000 claims description 15
• 239000003937 drug carrier Substances 0.000 claims 1
• 239000013612 plasmid Substances 0.000 abstract description 118
• 108020004414 DNA Proteins 0.000 abstract description 112
• 102000004196 processed proteins & peptides Human genes 0.000 abstract description 88
• 238000000034 method Methods 0.000 abstract description 65
• 241000700605 Viruses Species 0.000 abstract description 61
• 239000013598 vector Substances 0.000 abstract description 46
• 230000014509 gene expression Effects 0.000 abstract description 45
• 229960005486 vaccine Drugs 0.000 abstract description 44
• 230000003053 immunization Effects 0.000 abstract description 35
• 238000002649 immunization Methods 0.000 abstract description 33
• 208000015181 infectious disease Diseases 0.000 abstract description 29
• 101710116435 Outer membrane protein Proteins 0.000 abstract description 24
• 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 23
• 241001465754 Metazoa Species 0.000 abstract description 22
• 108020004511 Recombinant DNA Proteins 0.000 abstract description 20
• 238000000746 purification Methods 0.000 abstract description 18
• 238000003556 assay Methods 0.000 abstract description 16
• 238000009396 hybridization Methods 0.000 abstract description 9
• 241000238631 Hexapoda Species 0.000 abstract description 7
• 239000000126 substance Substances 0.000 abstract description 7
• 230000001976 improved effect Effects 0.000 abstract description 4
• 241001515965 unidentified phage Species 0.000 abstract description 4
• 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
• 238000003018 immunoassay Methods 0.000 abstract description 2
• 108060003951 Immunoglobulin Proteins 0.000 abstract 1
• 108020005202 Viral DNA Proteins 0.000 abstract 1
• 102000018358 immunoglobulin Human genes 0.000 abstract 1
• 229940072221 immunoglobulins Drugs 0.000 abstract 1
• 235000018102 proteins Nutrition 0.000 description 215
• 210000004027 cell Anatomy 0.000 description 126
• 239000012634 fragment Substances 0.000 description 94
• 230000000844 anti-bacterial effect Effects 0.000 description 75
• 229940024606 amino acid Drugs 0.000 description 68
• 235000001014 amino acid Nutrition 0.000 description 68
• 150000001413 amino acids Chemical group 0.000 description 65
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 52
• 241000283973 Oryctolagus cuniculus Species 0.000 description 42
• 238000004458 analytical method Methods 0.000 description 38
• 239000000499 gel Substances 0.000 description 38
• 239000012528 membrane Substances 0.000 description 38
• 239000000872 buffer Substances 0.000 description 29
• 230000000694 effects Effects 0.000 description 28
• 239000011780 sodium chloride Substances 0.000 description 27
• 238000001262 western blot Methods 0.000 description 27
• 238000002965 ELISA Methods 0.000 description 26
• 239000007983 Tris buffer Substances 0.000 description 26
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 26
• 239000003599 detergent Substances 0.000 description 25
• 238000012360 testing method Methods 0.000 description 25
• 238000013518 transcription Methods 0.000 description 25
• 239000000523 sample Substances 0.000 description 24
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 23
• 238000010790 dilution Methods 0.000 description 23
• 239000012895 dilution Substances 0.000 description 23
• 239000013604 expression vector Substances 0.000 description 23
• 239000002773 nucleotide Substances 0.000 description 23
• 125000003729 nucleotide group Chemical group 0.000 description 23
• 230000035897 transcription Effects 0.000 description 23
• 230000027455 binding Effects 0.000 description 22
• 210000002421 cell wall Anatomy 0.000 description 22
• 101710204837 Envelope small membrane protein Proteins 0.000 description 21
• 239000000562 conjugate Substances 0.000 description 21
• 239000000047 product Substances 0.000 description 21
• 230000009257 reactivity Effects 0.000 description 21
• 238000000605 extraction Methods 0.000 description 20
• 230000004927 fusion Effects 0.000 description 20
• 238000003780 insertion Methods 0.000 description 20
• 230000037431 insertion Effects 0.000 description 20
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 19
• 241000699666 Mus <mouse, genus> Species 0.000 description 19
• 241000700159 Rattus Species 0.000 description 19
• 238000010276 construction Methods 0.000 description 19
• 150000004665 fatty acids Chemical class 0.000 description 19
• 101710145006 Lysis protein Proteins 0.000 description 18
• 108700026244 Open Reading Frames Proteins 0.000 description 18
• 210000004369 blood Anatomy 0.000 description 18
• 239000008280 blood Substances 0.000 description 18
• 238000006243 chemical reaction Methods 0.000 description 18
• 238000010367 cloning Methods 0.000 description 18
• 235000014113 dietary fatty acids Nutrition 0.000 description 18
• 229930195729 fatty acid Natural products 0.000 description 18
• 239000000194 fatty acid Substances 0.000 description 18
• 238000002360 preparation method Methods 0.000 description 18
• 238000012163 sequencing technique Methods 0.000 description 18
• 230000001580 bacterial effect Effects 0.000 description 17
• 230000001681 protective effect Effects 0.000 description 17
• 241000894006 Bacteria Species 0.000 description 16
• 238000002955 isolation Methods 0.000 description 16
• 238000004519 manufacturing process Methods 0.000 description 16
• 230000014616 translation Effects 0.000 description 16
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
• 108090001030 Lipoproteins Proteins 0.000 description 15
• 102000004895 Lipoproteins Human genes 0.000 description 15
• 108010076504 Protein Sorting Signals Proteins 0.000 description 15
• 238000005119 centrifugation Methods 0.000 description 15
• 230000001086 cytosolic effect Effects 0.000 description 15
• 108091008146 restriction endonucleases Proteins 0.000 description 15
• 239000002671 adjuvant Substances 0.000 description 14
• 229940037003 alum Drugs 0.000 description 14
• 239000000284 extract Substances 0.000 description 14
• 239000006166 lysate Substances 0.000 description 14
• 238000013519 translation Methods 0.000 description 14
• 241000606790 Haemophilus Species 0.000 description 13
• 241000699670 Mus sp. Species 0.000 description 13
• 238000002474 experimental method Methods 0.000 description 13
• 210000004408 hybridoma Anatomy 0.000 description 13
• 108020004705 Codon Proteins 0.000 description 12
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 12
• 241000700618 Vaccinia virus Species 0.000 description 12
• 210000000349 chromosome Anatomy 0.000 description 12
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
• 239000002953 phosphate buffered saline Substances 0.000 description 12
• 210000002966 serum Anatomy 0.000 description 12
• 238000003786 synthesis reaction Methods 0.000 description 12
• 230000000295 complement effect Effects 0.000 description 11
• 239000002158 endotoxin Substances 0.000 description 11
• 230000002209 hydrophobic effect Effects 0.000 description 11
• 230000028993 immune response Effects 0.000 description 11
• 108020004999 messenger RNA Proteins 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 239000012130 whole-cell lysate Substances 0.000 description 11
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
• 201000009906 Meningitis Diseases 0.000 description 10
• 108091081024 Start codon Proteins 0.000 description 10
• 230000005875 antibody response Effects 0.000 description 10
• 230000029087 digestion Effects 0.000 description 10
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 10
• 229920006008 lipopolysaccharide Polymers 0.000 description 10
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 9
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
• VFGBXFZXJAWPOE-PEOIOWGVSA-N CCCCCC[C@H]1OC(=O)CNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)CC)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H]1C Chemical compound CCCCCC[C@H]1OC(=O)CNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)CC)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H]1C VFGBXFZXJAWPOE-PEOIOWGVSA-N 0.000 description 9
• 102000053602 DNA Human genes 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• VFGBXFZXJAWPOE-UHFFFAOYSA-N Globomycin Natural products CCCCCCC1OC(=O)CNC(=O)C(C(C)O)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)N(C)C(=O)C1C VFGBXFZXJAWPOE-UHFFFAOYSA-N 0.000 description 9
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
• 239000000020 Nitrocellulose Substances 0.000 description 9
• 108010033276 Peptide Fragments Proteins 0.000 description 9
• 102000007079 Peptide Fragments Human genes 0.000 description 9
• 230000002788 anti-peptide Effects 0.000 description 9
• 201000010099 disease Diseases 0.000 description 9
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
• 229940088598 enzyme Drugs 0.000 description 9
• 108010081886 globomycin Proteins 0.000 description 9
• 229920001220 nitrocellulos Polymers 0.000 description 9
• 230000036961 partial effect Effects 0.000 description 9
• 239000012071 phase Substances 0.000 description 9
• 229920001184 polypeptide Polymers 0.000 description 9
• 230000002797 proteolythic effect Effects 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 238000010561 standard procedure Methods 0.000 description 9
• 241000701447 unidentified baculovirus Species 0.000 description 9
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 8
• 241000700114 Chinchillidae Species 0.000 description 8
• 108091026890 Coding region Proteins 0.000 description 8
• 239000002775 capsule Substances 0.000 description 8
• 238000012512 characterization method Methods 0.000 description 8
• 230000000875 corresponding effect Effects 0.000 description 8
• IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical group CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
• 239000011541 reaction mixture Substances 0.000 description 8
• 238000010186 staining Methods 0.000 description 8
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
• 238000012286 ELISA Assay Methods 0.000 description 7
• 241000282412 Homo Species 0.000 description 7
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
• 206010033078 Otitis media Diseases 0.000 description 7
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 7
• 238000010171 animal model Methods 0.000 description 7
• 239000000427 antigen Substances 0.000 description 7
• 108091007433 antigens Proteins 0.000 description 7
• 102000036639 antigens Human genes 0.000 description 7
• 238000004587 chromatography analysis Methods 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 230000005847 immunogenicity Effects 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 229930182817 methionine Natural products 0.000 description 7
• 229920001282 polysaccharide Polymers 0.000 description 7
• 239000005017 polysaccharide Substances 0.000 description 7
• 230000002441 reversible effect Effects 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 238000012546 transfer Methods 0.000 description 7
• 238000011282 treatment Methods 0.000 description 7
• 229920000936 Agarose Polymers 0.000 description 6
• 102000012410 DNA Ligases Human genes 0.000 description 6
• 108010061982 DNA Ligases Proteins 0.000 description 6
• 102000004594 DNA Polymerase I Human genes 0.000 description 6
• 108010017826 DNA Polymerase I Proteins 0.000 description 6
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 206010065838 Middle ear inflammation Diseases 0.000 description 6
• 102000016943 Muramidase Human genes 0.000 description 6
• 108010014251 Muramidase Proteins 0.000 description 6
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 6
• 108091034117 Oligonucleotide Proteins 0.000 description 6
• -1 S-lactoglobulin Proteins 0.000 description 6
• 238000012300 Sequence Analysis Methods 0.000 description 6
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
• 229920004890 Triton X-100 Polymers 0.000 description 6
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
• BHATUINFZWUDIX-UHFFFAOYSA-N Zwittergent 3-14 Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O BHATUINFZWUDIX-UHFFFAOYSA-N 0.000 description 6
• 230000000996 additive effect Effects 0.000 description 6
• 238000000246 agarose gel electrophoresis Methods 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 6
• 238000001962 electrophoresis Methods 0.000 description 6
• 150000004676 glycans Chemical class 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 230000002458 infectious effect Effects 0.000 description 6
• 239000004325 lysozyme Substances 0.000 description 6
• 229960000274 lysozyme Drugs 0.000 description 6
• 235000010335 lysozyme Nutrition 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• 239000008188 pellet Substances 0.000 description 6
• 239000000863 peptide conjugate Substances 0.000 description 6
• ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 6
• 235000014347 soups Nutrition 0.000 description 6
• 230000009466 transformation Effects 0.000 description 6
• 230000017105 transposition Effects 0.000 description 6
• 238000002255 vaccination Methods 0.000 description 6
• 229920001817 Agar Polymers 0.000 description 5
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
• 108090000301 Membrane transport proteins Proteins 0.000 description 5
• 102000003939 Membrane transport proteins Human genes 0.000 description 5
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 5
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• 239000007984 Tris EDTA buffer Substances 0.000 description 5
• 239000008272 agar Substances 0.000 description 5
• 239000003242 anti bacterial agent Substances 0.000 description 5
• 238000009534 blood test Methods 0.000 description 5
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 5
• 239000013599 cloning vector Substances 0.000 description 5
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
• 235000018417 cysteine Nutrition 0.000 description 5
• 238000012217 deletion Methods 0.000 description 5
• 230000037430 deletion Effects 0.000 description 5
• 229940009976 deoxycholate Drugs 0.000 description 5
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 238000010438 heat treatment Methods 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 229910001629 magnesium chloride Inorganic materials 0.000 description 5
• 230000009061 membrane transport Effects 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 238000010369 molecular cloning Methods 0.000 description 5
• HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 5
• 229920002776 polycyclohexyl methacrylate Polymers 0.000 description 5
• 229920000136 polysorbate Polymers 0.000 description 5
• 239000013615 primer Substances 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 230000000717 retained effect Effects 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• 238000005063 solubilization Methods 0.000 description 5
• 230000007928 solubilization Effects 0.000 description 5
• 230000014621 translational initiation Effects 0.000 description 5
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
• 235000002374 tyrosine Nutrition 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• TUBRCQBRKJXJEA-UHFFFAOYSA-N 3-[hexadecyl(dimethyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O TUBRCQBRKJXJEA-UHFFFAOYSA-N 0.000 description 4
• 239000004475 Arginine Substances 0.000 description 4
• 206010003445 Ascites Diseases 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• 241000700112 Chinchilla Species 0.000 description 4
• 108010053187 Diphtheria Toxin Proteins 0.000 description 4
• 102000016607 Diphtheria Toxin Human genes 0.000 description 4
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• 239000004472 Lysine Substances 0.000 description 4
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• 229920002125 Sokalan® Polymers 0.000 description 4
• 102000009843 Thyroglobulin Human genes 0.000 description 4
• 108010034949 Thyroglobulin Proteins 0.000 description 4
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 239000000654 additive Substances 0.000 description 4
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
• 235000009697 arginine Nutrition 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 229940098773 bovine serum albumin Drugs 0.000 description 4
• 230000021615 conjugation Effects 0.000 description 4
• 238000000502 dialysis Methods 0.000 description 4
• 230000008029 eradication Effects 0.000 description 4
• 238000001502 gel electrophoresis Methods 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 230000036039 immunity Effects 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 238000011081 inoculation Methods 0.000 description 4
• 239000002198 insoluble material Substances 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 238000005342 ion exchange Methods 0.000 description 4
• 238000002156 mixing Methods 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 201000000050 myeloid neoplasm Diseases 0.000 description 4
• ISYWECDDZWTKFF-UHFFFAOYSA-N nonadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)=O ISYWECDDZWTKFF-UHFFFAOYSA-N 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
• 239000010452 phosphate Substances 0.000 description 4
• 238000001556 precipitation Methods 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000003248 secreting effect Effects 0.000 description 4
• 235000004400 serine Nutrition 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 238000000527 sonication Methods 0.000 description 4
• 210000004989 spleen cell Anatomy 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 229960002175 thyroglobulin Drugs 0.000 description 4
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
• 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 3
• 101100205313 Caenorhabditis elegans nars-1 gene Proteins 0.000 description 3
• 241000701959 Escherichia virus Lambda Species 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 206010061190 Haemophilus infection Diseases 0.000 description 3
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• 239000005639 Lauric acid Substances 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• 102000003960 Ligases Human genes 0.000 description 3
• 108090000364 Ligases Proteins 0.000 description 3
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
• 235000021314 Palmitic acid Nutrition 0.000 description 3
• 101710088839 Replication initiation protein Proteins 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 235000009582 asparagine Nutrition 0.000 description 3
• 229960001230 asparagine Drugs 0.000 description 3
• 235000003704 aspartic acid Nutrition 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 244000309466 calf Species 0.000 description 3
• 239000004202 carbamide Substances 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 238000000354 decomposition reaction Methods 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 239000005546 dideoxynucleotide Substances 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 230000007717 exclusion Effects 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 235000013922 glutamic acid Nutrition 0.000 description 3
• 239000004220 glutamic acid Substances 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 235000004554 glutamine Nutrition 0.000 description 3
• 229940025294 hemin Drugs 0.000 description 3
• BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 230000000521 hyperimmunizing effect Effects 0.000 description 3
• 238000012744 immunostaining Methods 0.000 description 3
• 229940031551 inactivated vaccine Drugs 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 238000004255 ion exchange chromatography Methods 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 239000002808 molecular sieve Substances 0.000 description 3
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
• 235000015097 nutrients Nutrition 0.000 description 3
• 239000002751 oligonucleotide probe Substances 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 150000002942 palmitic acid derivatives Chemical class 0.000 description 3
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 239000013600 plasmid vector Substances 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 230000006337 proteolytic cleavage Effects 0.000 description 3
• 238000003127 radioimmunoassay Methods 0.000 description 3
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
• 238000004007 reversed phase HPLC Methods 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 229960002898 threonine Drugs 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 230000001960 triggered effect Effects 0.000 description 3
• 239000004474 valine Substances 0.000 description 3
• FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 2
• PYAFUXYGTYWWBP-UHFFFAOYSA-N 19-methoxynonadecane-1,2,3-triol Chemical compound COCCCCCCCCCCCCCCCCC(O)C(O)CO PYAFUXYGTYWWBP-UHFFFAOYSA-N 0.000 description 2
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 2
• LYFYWXLKKQIOKO-UHFFFAOYSA-N 3,3-diaminopentan-1-ol Chemical compound CCC(N)(N)CCO LYFYWXLKKQIOKO-UHFFFAOYSA-N 0.000 description 2
• UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
• GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 2
• 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
• 208000031729 Bacteremia Diseases 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 108010038061 Chymotrypsinogen Proteins 0.000 description 2
• 239000003298 DNA probe Substances 0.000 description 2
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
• RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 2
• KUGRPPRAQNPSQD-UHFFFAOYSA-N OOOOO Chemical compound OOOOO KUGRPPRAQNPSQD-UHFFFAOYSA-N 0.000 description 2
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 2
• 241000283977 Oryctolagus Species 0.000 description 2
• 108010058846 Ovalbumin Proteins 0.000 description 2
• 108090000445 Parathyroid hormone Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 101710182846 Polyhedrin Proteins 0.000 description 2
• 239000004793 Polystyrene Substances 0.000 description 2
• 102100036829 Probable peptidyl-tRNA hydrolase Human genes 0.000 description 2
• 102000055027 Protein Methyltransferases Human genes 0.000 description 2
• 108700040121 Protein Methyltransferases Proteins 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 239000004098 Tetracycline Substances 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 108020004440 Thymidine kinase Proteins 0.000 description 2
• 108700009124 Transcription Initiation Site Proteins 0.000 description 2
• 108010084754 Tuftsin Proteins 0.000 description 2
• 206010046865 Vaccinia virus infection Diseases 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 230000010933 acylation Effects 0.000 description 2
• 238000005917 acylation reaction Methods 0.000 description 2
• 239000011543 agarose gel Substances 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
• 235000011130 ammonium sulphate Nutrition 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• 150000008064 anhydrides Chemical class 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000003125 aqueous solvent Substances 0.000 description 2
• 239000013602 bacteriophage vector Substances 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 239000012267 brine Substances 0.000 description 2
• 238000012754 cardiac puncture Methods 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 239000007857 degradation product Substances 0.000 description 2
• 229960000633 dextran sulfate Drugs 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
• 108700003601 dimethylglycine Proteins 0.000 description 2
• 229960003983 diphtheria toxoid Drugs 0.000 description 2
• NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 2
• 210000003027 ear inner Anatomy 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 238000012869 ethanol precipitation Methods 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 235000013861 fat-free Nutrition 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 230000005714 functional activity Effects 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 210000004201 immune sera Anatomy 0.000 description 2
• 229940042743 immune sera Drugs 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 239000012535 impurity Substances 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 238000001155 isoelectric focusing Methods 0.000 description 2
• 229930027917 kanamycin Natural products 0.000 description 2
• 229960000318 kanamycin Drugs 0.000 description 2
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
• 229930182823 kanamycin A Natural products 0.000 description 2
• IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 238000004811 liquid chromatography Methods 0.000 description 2
• 239000012160 loading buffer Substances 0.000 description 2
• 230000005923 long-lasting effect Effects 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 229940098779 methanesulfonic acid Drugs 0.000 description 2
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 235000010755 mineral Nutrition 0.000 description 2
• 229940031348 multivalent vaccine Drugs 0.000 description 2
• BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 235000016709 nutrition Nutrition 0.000 description 2
• 230000001662 opsonic effect Effects 0.000 description 2
• 229940092253 ovalbumin Drugs 0.000 description 2
• 235000020030 perry Nutrition 0.000 description 2
• 239000002504 physiological saline solution Substances 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 239000004584 polyacrylic acid Substances 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229920002223 polystyrene Polymers 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 201000005484 prostate carcinoma in situ Diseases 0.000 description 2
• KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 210000003705 ribosome Anatomy 0.000 description 2
• 238000004062 sedimentation Methods 0.000 description 2
• 238000011451 sequencing strategy Methods 0.000 description 2
• 238000002791 soaking Methods 0.000 description 2
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
• 125000006850 spacer group Chemical group 0.000 description 2
• ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
• 238000012453 sprague-dawley rat model Methods 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 229960002180 tetracycline Drugs 0.000 description 2
• 229930101283 tetracycline Natural products 0.000 description 2
• 235000019364 tetracycline Nutrition 0.000 description 2
• 150000003522 tetracyclines Chemical class 0.000 description 2
• 235000008521 threonine Nutrition 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 230000005026 transcription initiation Effects 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
• IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 2
• 229940035670 tuftsin Drugs 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 208000007089 vaccinia Diseases 0.000 description 2
• LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• 101150029062 15 gene Proteins 0.000 description 1
• 108020004465 16S ribosomal RNA Proteins 0.000 description 1
• NJDPBWLDVFCXNP-UHFFFAOYSA-N 2-cyanoethyl dihydrogen phosphate Chemical group OP(O)(=O)OCCC#N NJDPBWLDVFCXNP-UHFFFAOYSA-N 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
• OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
• ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
• 102000007566 ATP-Dependent Proteases Human genes 0.000 description 1
• 108010071550 ATP-Dependent Proteases Proteins 0.000 description 1
• 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• 239000005695 Ammonium acetate Substances 0.000 description 1
• 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
• 241001203868 Autographa californica Species 0.000 description 1
• 238000000035 BCA protein assay Methods 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 241000167854 Bourreria succulenta Species 0.000 description 1
• 101800001415 Bri23 peptide Proteins 0.000 description 1
• SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 101800000655 C-terminal peptide Proteins 0.000 description 1
• 102400000107 C-terminal peptide Human genes 0.000 description 1
• INIUQQPMCFQBDT-UHFFFAOYSA-N C1(=CC=CC=C1)N1C(=S)NC(=O)C1.N(C1=CC=CC=C1)C1=NC(SC1)=O Chemical compound C1(=CC=CC=C1)N1C(=S)NC(=O)C1.N(C1=CC=CC=C1)C1=NC(SC1)=O INIUQQPMCFQBDT-UHFFFAOYSA-N 0.000 description 1
• OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 230000007067 DNA methylation Effects 0.000 description 1
• 230000008836 DNA modification Effects 0.000 description 1
• 239000003155 DNA primer Substances 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 238000007900 DNA-DNA hybridization Methods 0.000 description 1
• 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
• 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 108010067770 Endopeptidase K Proteins 0.000 description 1
• 241001131785 Escherichia coli HB101 Species 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
• 108010008488 Glycylglycine Proteins 0.000 description 1
• 229940124865 Haemophilus vaccine Drugs 0.000 description 1
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
• 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 description 1
• 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
• 108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 1
• 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 108010054278 Lac Repressors Proteins 0.000 description 1
• 102000008192 Lactoglobulins Human genes 0.000 description 1
• 108010060630 Lactoglobulins Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010065735 Laryngeal inflammation Diseases 0.000 description 1
• 201000008197 Laryngitis Diseases 0.000 description 1
• 241001625930 Luria Species 0.000 description 1
• 239000006142 Luria-Bertani Agar Substances 0.000 description 1
• 101710185515 Major outer membrane lipoprotein Lpp Proteins 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 101710169959 Membrane protein 2 Proteins 0.000 description 1
• 206010027202 Meningitis bacterial Diseases 0.000 description 1
• 206010027241 Meningitis haemophilus Diseases 0.000 description 1
• 206010058780 Meningitis neonatal Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 208000006816 Neonatal Sepsis Diseases 0.000 description 1
• 208000005141 Otitis Diseases 0.000 description 1
• 241000364057 Peoria Species 0.000 description 1
• 101710176384 Peptide 1 Proteins 0.000 description 1
• 101800004191 Peptide P2 Proteins 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 206010035148 Plague Diseases 0.000 description 1
• 206010036422 Postpartum sepsis Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 208000020264 Puerperal Infection Diseases 0.000 description 1
• 239000005700 Putrescine Substances 0.000 description 1
• 230000004570 RNA-binding Effects 0.000 description 1
• 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
• 108020005091 Replication Origin Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 241000702208 Shigella phage SfX Species 0.000 description 1
• 108090000233 Signal peptidase II Proteins 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
• 241000191940 Staphylococcus Species 0.000 description 1
• 108010008038 Synthetic Vaccines Proteins 0.000 description 1
• 244000297179 Syringa vulgaris Species 0.000 description 1
• 235000004338 Syringa vulgaris Nutrition 0.000 description 1
• 101150003725 TK gene Proteins 0.000 description 1
• 108010055044 Tetanus Toxin Proteins 0.000 description 1
• 241001664469 Tibicina haematodes Species 0.000 description 1
• 206010044314 Tracheobronchitis Diseases 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 101710162629 Trypsin inhibitor Proteins 0.000 description 1
• 229940122618 Trypsin inhibitor Drugs 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• CDXSJGDDABYYJV-UHFFFAOYSA-N acetic acid;ethanol Chemical compound CCO.CC(O)=O CDXSJGDDABYYJV-UHFFFAOYSA-N 0.000 description 1
• 108091005646 acetylated proteins Proteins 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 229960001570 ademetionine Drugs 0.000 description 1
• 238000005273 aeration Methods 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 150000001408 amides Chemical group 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 235000019257 ammonium acetate Nutrition 0.000 description 1
• 229940043376 ammonium acetate Drugs 0.000 description 1
• 239000001166 ammonium sulphate Substances 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 235000021120 animal protein Nutrition 0.000 description 1
• 230000003171 anti-complementary effect Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 101150042295 arfA gene Proteins 0.000 description 1
• 201000009904 bacterial meningitis Diseases 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229940041514 candida albicans extract Drugs 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 235000019693 cherries Nutrition 0.000 description 1
• 238000011098 chromatofocusing Methods 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229940001442 combination vaccine Drugs 0.000 description 1
• 239000012468 concentrated sample Substances 0.000 description 1
• 239000005289 controlled pore glass Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 101150054175 cro gene Proteins 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 230000037029 cross reaction Effects 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 239000012531 culture fluid Substances 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000002498 deadly effect Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 239000000645 desinfectant Substances 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 238000011026 diafiltration Methods 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 238000007598 dipping method Methods 0.000 description 1
• KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 208000019258 ear infection Diseases 0.000 description 1
• 239000012149 elution buffer Substances 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 125000005313 fatty acid group Chemical group 0.000 description 1
• 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
• 125000001924 fatty-acyl group Chemical group 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 238000001030 gas--liquid chromatography Methods 0.000 description 1
• 238000001641 gel filtration chromatography Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 238000012248 genetic selection Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
• 208000010523 haemophilus meningitis Diseases 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 239000012145 high-salt buffer Substances 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 208000022760 infectious otitis media Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
• 229960002064 kanamycin sulfate Drugs 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 108010012584 lac alpha peptide Proteins 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 231100000636 lethal dose Toxicity 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 125000003473 lipid group Chemical group 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000009630 liquid culture Methods 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 150000004702 methyl esters Chemical class 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 238000002715 modification method Methods 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 230000000422 nocturnal effect Effects 0.000 description 1
• 102000042567 non-coding RNA Human genes 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 239000006916 nutrient agar Substances 0.000 description 1
• 101150087557 omcB gene Proteins 0.000 description 1
• 101150115693 ompA gene Proteins 0.000 description 1
• 101150073640 ompF gene Proteins 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 238000000643 oven drying Methods 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 108010083127 phage repressor proteins Proteins 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 229940067631 phospholipid Drugs 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 238000009021 pre-vaccination Methods 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 238000002731 protein assay Methods 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000003156 radioimmunoprecipitation Methods 0.000 description 1
• 108091007054 readthrough proteins Proteins 0.000 description 1
• 101150079601 recA gene Proteins 0.000 description 1
• 229940124551 recombinant vaccine Drugs 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 108020004418 ribosomal RNA Proteins 0.000 description 1
• 108700004121 sarkosyl Proteins 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 201000009890 sinusitis Diseases 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 229940083538 smallpox vaccine Drugs 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 229960004025 sodium salicylate Drugs 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• HRSIEGIETAEGEO-UHFFFAOYSA-M sodium;acetonitrile;acetate Chemical compound [Na+].CC#N.CC([O-])=O HRSIEGIETAEGEO-UHFFFAOYSA-M 0.000 description 1
• 238000010532 solid phase synthesis reaction Methods 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 239000001593 sorbitan monooleate Substances 0.000 description 1
• 235000011069 sorbitan monooleate Nutrition 0.000 description 1
• 229940035049 sorbitan monooleate Drugs 0.000 description 1
• 229940063673 spermidine Drugs 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 229940118376 tetanus toxin Drugs 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 230000012863 translational readthrough Effects 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
• 239000012646 vaccine adjuvant Substances 0.000 description 1
• 229940124931 vaccine adjuvant Drugs 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 229960004854 viral vaccine Drugs 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• 239000012138 yeast extract Substances 0.000 description 1